Therapeutic effect of human ghrelin and growth hormone: Attenuation of immunosuppression in septic aged rats

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1863, Issue 10, 2017, Pages 2584-2593

  Zhou, Mian ^a   Yang, Weng Lang ^a,b   Aziz, Monowar ^a   Ma, Gaifeng ^a   Wang, Ping ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Aging; Ghrelin; Growth hormone; Immunosuppression; Sepsis

Indexed keywords

CD3 ANTIBODY; GAMMA INTERFERON; GHRELIN; GROWTH HORMONE; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY CD28; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR; CYTOKINE; HUMAN GROWTH HORMONE; PROGRAMMED DEATH 1 RECEPTOR;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CELL ISOLATION; CONTROLLED STUDY; EX VIVO STUDY; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; SEPSIS; SPLEEN; SPLEEN CELL; THERAPY EFFECT; AGING; ANIMAL; DRUG EFFECT; FISCHER 344 RAT; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY;

AGING; ANIMALS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; GHRELIN; HUMAN GROWTH HORMONE; HUMANS; IMMUNOSUPPRESSION; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR; RATS; RATS, INBRED F344; SEPSIS; T-LYMPHOCYTES, REGULATORY;

EID: 85012277292     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2017.01.014     Document Type: Article

References (63)

1. Gustot, T., Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response. Curr. Opin. Crit. Care 17 (2011), 153–159.
2. Dombrovskiy, V.Y., Martin, A.A., Sunderram, J., Paz, H.L., Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit. Care Med. 35 (2007), 1244–1250.
3. Boomer, J.S., K. To, Chang, K.C., Takasu, O., Osborne, D.F., Walton, A.H., Bricker, T.L., Jarman, S.D. II, Kreisel, D., Krupnick, A.S., Srivastava, A., Swanson, P.E., Green, J.M., Hotchkiss, R.S., Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306 (2011), 2594–2605.
4. Dinarello, C.A., Anti-cytokine therapies in response to systemic infection. J. Investig. Dermatol. Symp. Proc. 6 (2001), 244–250.
5. Minnich, D.J., Moldawer, L.L., Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls. Proc. Nutr. Soc. 63 (2004), 437–441.
6. Dinarello, C.A., Abraham, E., Does blocking cytokines in sepsis work?. Am. J. Respir. Crit. Care Med. 166 (2002), 1156–1157.
7. Vincent, J.L., Abraham, E., Annane, D., Bernard, G., Rivers, E., Van den Berghe, G., Reducing mortality in sepsis: new directions. Crit. Care 6:Suppl. 3 (2002), S1–18.
8. O'Brien, J.M., Abraham, E., New approaches to the treatment of sepsis. Clin. Chest Med. 24 (2003), 521–548.
9. Hotchkiss, R.S., Karl, I.E., The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348 (2003), 138–150.
10. Hotchkiss, R.S., Monneret, G., Payen, D., Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13 (2013), 260–268.
11. Oberholzer, A., Oberholzer, C., Moldawer, L.L., Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16 (2001), 83–96.
12. Martin, G.S., Mannino, D.M., Moss, M., The effect of age on the development and outcome of adult sepsis. Crit. Care Med. 34 (2006), 15–21.
13. Bermejo-Martin, J.F., Andaluz-Ojeda, D., Almansa, R., Gandía, F., Gómez-Herreras, J.I., Gomez-Sanchez, E., Heredia-Rodriguez, M., Eiros, J.M., Kelvin, D.J., Tamayo, E., Defining immunological dysfunction in sepsis: a requisite tool for precision medicine. J. Infect. 72 (2016), 525–536.
14. Arvat, E., Di Vito, L., Broglio, F., Papotti, M., Muccioli, G., Dieguez, C., Casanueva, F.F., Deghenghi, R., Camanni, F., Ghigo, E., Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J. Endocrinol. Investig. 23 (2000), 493–495.
15. Wu, J.T., Kral, J.G., Ghrelin: integrative neuroendocrine peptide in health and disease. Ann. Surg. 239 (2004), 464–474.
16. Wu, R., Dong, W., Zhou, M., Zhang, F., Marini, C.P., Ravikumar, T.S., Wang, P., Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am. J. Respir. Crit. Care Med. 176 (2007), 805–813.
17. Gonzalez-Rey, E., Chorny, A., Delgado, M., Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 130 (2006), 1707–1720.
18. Wu, R., Zhou, M., Cui, X., Simms, H.H., Wang, P., Upregulation of cardiovascular ghrelin receptor occurs in the hyperdynamic phase of sepsis. Am. J. Physiol. Heart Circ. Physiol. 287 (2004), H1296–H1302.
19. Wu, R., Zhou, M., Dong, W., Ji, Y., Miksa, M., Marini, C.P., Ravikumar, T.S., Wang, P., Ghrelin hyporesponsiveness contributes to age-related hyperinflammation in septic shock. Ann. Surg. 250 (2009), 126–133.
20. Vila, G., Maier, C., Riedl, M., Nowotny, P., Ludvik, B., Luger, A., Clodi, M., Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. J. Clin. Endocrinol. Metab. 92 (2007), 3930–3934.
21. Koch, A., Sanson, E., Helm, A., Voigt, S., Trautwein, C., Tacke, F., Regulation and prognostic relevance of serum ghrelin concentrations in critical illness and sepsis. Crit. Care, 14, 2010, R94.
22. Yang, W.L., Ma, G., Zhou, M., Aziz, M., Yen, H.T., Mavropoulos, S., Ojamaa, K., Wang, P., Combined administration of human ghrelin and human growth hormone attenuates organ injury and improves survival in aged septic rats. Mol. Med. 22 (2016), 124–135.
23. Trickett, A., Kwan, Y.L., T cell stimulation and expansion using anti-CD3/CD28 beads. J. Immunol. Methods 275 (2003), 251–255.
24. Hotchkiss, R.S., Tinsley, K.W., Swanson, P.E., Schmieg, R.E., Hui, J.J., Chang, K.C., Osborne, D.F., Freeman, B.D., Cobb, J.P., Buchman, T.G., Karl, I.E., Sepsis-induced apoptosis causes progressive profound depletion of B and CD4 + T lymphocytes in humans. J. Immunol. 166 (2001), 6952–6963.
25. Penaloza-MacMaster, P., Kamphorst, A.O., Wieland, A., Araki, K., Iyer, S.S., West, E.E., O'Mara, L., Yang, S., Konieczny, B.T., Sharpe, A.H., Freeman, G.J., Rudensky, A.Y., Ahmed, R., Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J. Exp. Med. 211 (2014), 1905–1918.
26. El-Osta, H., Shahid, K., Mills, G.M., Peddi, P., Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther. 9 (2016), 5101–5116.
27. Sheppard, K.A., Fitz, L.J., Lee, J.M., Benander, C., George, J.A., Wooters, J., Qiu, Y., Jussif, J.M., Carter, L.L., Wood, C.R., Chaudhary, D., PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574 (2004), 37–41.
28. Velu, V., Shetty, R.D., Larsson, M., Shankar, E.M., Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology, 12, 2015, 14.
29. Inoue, S., Bo, L., Bian, J., Unsinger, J., Chang, K., Hotchkiss, R.S., Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock 36 (2011), 38–44.
30. Santarpia, M., González-Cao, M., Viteri, S., Karachaliou, N., Altavilla, G., Rosell, R., Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl. Lung. Cancer Res. 4 (2015), 728–742.
31. Matsushima, G.K., Itoh-Lindstrom, Y., Ting, J.P., Activation of the HLA-DRA gene in primary human T lymphocytes: novel usage of TATA and the X and Y promoter elements. Mol. Cell. Biol. 12 (1992), 5610–5619.
32. Rimmelé, T., Payen, D., Cantaluppi, V., Marshall, J., Gomez, H., Gomez, A., Murray, P., Kellum, J.A., Workgroup, A.X., Immune cell phenotype and function in sepsis. Shock 45 (2016), 282–291.
33. Deitch, E.A., Animal models of sepsis and shock: a review and lessons learned. Shock 9 (1998), 1–11.
34. Hotchkiss, R.S., Monneret, G., Payen, D., Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 13 (2013), 862–874.
35. Xiao, W., Mindrinos, M.N., Seok, J., Cuschieri, J., Cuenca, A.G., Gao, H., Hayden, D.L., Hennessy, L., Moore, E.E., Minei, J.P., Bankey, P.E., Johnson, J.L., Sperry, J., Nathens, A.B., Billiar, T.R., West, M.A., Brownstein, B.H., Mason, P.H., Baker, H.V., Finnerty, C.C., Jeschke, M.G., Lopez, M.C., Klein, M.B., Gamelli, R.L., Gibran, N.S., Arnoldo, B., Xu, W., Zhang, Y., Calvano, S.E., McDonald-Smith, G.P., Schoenfeld, D.A., Storey, J.D., Cobb, J.P., Warren, H.S., Moldawer, L.L., Herndon, D.N., Lowry, S.F., Maier, R.V., Davis, R.W., Tompkins, R.G., Inflammation, P. Host response to injury large-scale collaborative research, a genomic storm in critically injured humans. J. Exp. Med. 208 (2011), 2581–2590.
36. Hotchkiss, R.S., Coopersmith, C.M., McDunn, J.E., Ferguson, T.A., The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 15 (2009), 496–497.
37. Imler, J.L., Hoffmann, J.A., Toll receptors in innate immunity. Trends Cell Biol. 11 (2001), 304–311.
38. Mebius, R.E., Kraal, G., Structure and function of the spleen. Nat. Rev. Immunol. 5 (2005), 606–616.
39. Delano, M.J., Ward, P.A., Sepsis-induced immune dysfunction: can immune therapies reduce mortality?. J. Clin. Invest. 126 (2016), 23–31.
40. Heidecke, C.D., Hensler, T., Weighardt, H., Zantl, N., Wagner, H., Siewert, J.R., Holzmann, B., Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am. J. Surg. 178 (1999), 288–292.
41. Hotchkiss, R.S., Nicholson, D.W., Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 6 (2006), 813–822.
42. Ni Choileain, N., MacConmara, M., Zang, Y., Murphy, T.J., Mannick, J.A., Lederer, J.A., Enhanced regulatory T cell activity is an element of the host response to injury. J. Immunol. 176 (2006), 225–236.
43. Hori, S., Nomura, T., Sakaguchi, S., Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003), 1057–1061.
44. Venet, F., Chung, C.S., Kherouf, H., Geeraert, A., Malcus, C., Poitevin, F., Bohe, J., Lepape, A., Ayala, A., Monneret, G., Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 35 (2009), 678–686.
45. Zhang, Y., Li, J., Lou, J., Zhou, Y., Bo, L., Zhu, J., Zhu, K., Wan, X., Cai, Z., Deng, X., Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit. Care, 15, 2011, R70.
46. Fife, B.T., Pauken, K.E., The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. N. Y. Acad. Sci. 1217 (2011), 45–59.
47. Chen, L., Flies, D.B., Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13 (2013), 227–242.
48. Lukaszewicz, A.C., Grienay, M., Resche-Rigon, M., Pirracchio, R., Faivre, V., Boval, B., Payen, D., Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit. Care Med. 37 (2009), 2746–2752.
49. Venet, F., Tissot, S., Debard, A.L., Faudot, C., Crampé, C., Pachot, A., Ayala, A., Monneret, G., Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: correlation with severity and secondary septic shock. Crit. Care Med. 35 (2007), 1910–1917.
50. Wu, R., Dong, W., Cui, X., Zhou, M., Simms, H.H., Ravikumar, T.S., Wang, P., Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann. Surg. 245 (2007), 480–486.
51. Buijs, R.M., van der Vliet, J., Garidou, M.L., Huitinga, I., Escobar, C., Spleen vagal denervation inhibits the production of antibodies to circulating antigens. PLoS One, 3, 2008, e3152.
52. Kojima, M., Kangawa, K., Ghrelin: structure and function. Physiol. Rev. 85 (2005), 495–522.
53. Dixit, V.D., Schaffer, E.M., Pyle, R.S., Collins, G.D., Sakthivel, S.K., Palaniappan, R., Lillard, J.W. Jr., Taub, D.D., Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J. Clin. Invest. 114 (2004), 57–66.
54. Bishop, N.C., Hayashida, H., Clark, M., Coombs, C., Miller, S., Stensel, D.J., Effect of acute and regular exercise on growth hormone secretagogue receptor-1a expression in human lymphocytes, T cell subpopulation and monocytes. Brain Behav. Immun. 39 (2014), 172–179.
55. Lee, J.H., Patel, K., Tae, H.J., Lustig, A., Kim, J.W., Mattson, M.P., Taub, D.D., Ghrelin augments murine T-cell proliferation by activation of the phosphatidylinositol-3-kinase, extracellular signal-regulated kinase and protein kinase C signaling pathways. FEBS Lett. 588 (2014), 4708–4719.
56. Patil, N.K., Bohannon, J.K., Sherwood, E.R., Immunotherapy: a promising approach to reverse sepsis-induced immunosuppression. Pharmacol. Res. 111 (2016), 688–702.
57. Chang, K.C., Burnham, C.A., Compton, S.M., Rasche, D.P., Mazuski, R.J., McDonough, J.S., Unsinger, J., Korman, A.J., Green, J.M., Hotchkiss, R.S., Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit. Care, 17, 2013, R85.
58. Huang, X., Venet, F., Wang, Y.L., Lepape, A., Yuan, Z., Chen, Y., Swan, R., Kherouf, H., Monneret, G., Chung, C.S., Ayala, A., PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 6303–6308.
59. Nalos, M., Santner-Nanan, B., Parnell, G., Tang, B., McLean, A.S., Nanan, R., Immune effects of interferon gamma in persistent staphylococcal sepsis. Am. J. Respir. Crit. Care Med. 185 (2012), 110–112.
60. Narula, T., deBoisblanc, B.P., Ghrelin in critical illness. Am. J. Respir. Cell Mol. Biol. 53 (2015), 437–442.
61. Takala, J., Ruokonen, E., Webster, N.R., Nielsen, M.S., Zandstra, D.F., Vundelinckx, G., Hinds, C.J., Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341 (1999), 785–792.
62. Wu, R., Chaung, W.W., Dong, W., Ji, Y., Barrera, R., Nicastro, J., Molmenti, E.P., Coppa, G.F., Wang, P., Ghrelin maintains the cardiovascular stability in severe sepsis. J. Surg. Res. 178 (2012), 370–377.
63. Wang, P., Chaudry, I.H., Mechanism of hepatocellular dysfunction during hyperdynamic sepsis. Am. J. Phys. 270 (1996), R927–R938.